Medtronic has announced that the U.S. Food and Drug Administration (FDA) has cleared the Hugo robotic-assisted surgery (RAS) ...

Medtronic’s Hugo robotic-assisted surgery system receives US FDA clearance for urologic surgical procedures: Galway, Ireland ...

FDA clears Medtronic robot for urologic surgeries, enabling use in prostatectomy, nephrectomy and cystectomy across select U.S. hospitals.

Medtronic's Hugo surgical robot gained FDA clearance for urologic procedures, opening U.S. market entry and setting the stage ...

Hugo RAS system brings choice to the U.S., coupled with the full suite of Medtronic surgical offerings, ultimately creating a ...

Medtronic (NYSE: MDT) announced today that the FDA cleared its Hugo robotic-assisted surgery system for use in urologic surgical procedures.

Medtronic (MDT) announced the FDA has cleared the Hugo robotic-assisted surgery, or RAS, system for use in urologic surgical procedures. The Hugo ...

Robotic surgery has become a leading option for various surgical procedures in recent years, both malignant and benign.

Patients who undergo single-port robotic prostate or kidney surgery tend to have less blood loss and postoperative pain and shorter hospital stays compared with patients undergoing multi-port robotic ...

Percutaneous cryoablation yields outcomes comparable to robotic surgery for renal cancer, at significantly lower cost and with a clear net monetary benefit, according to prospective real-world data ...